Treatment of Pediatric Contact Dermatitis

Initial Treatment Strategy

The American Academy of Pediatrics recommends using low to medium potency topical corticosteroids as first-line therapy for pediatric contact dermatitis, applied once to twice daily for 1-2 weeks, with potency selection based on the child's age, affected body site, and severity of inflammation 1
For children ages 0-6 years, lower potency formulations are recommended due to their high body surface area-to-volume ratio, which increases risk of hypothalamic-pituitary-adrenal (HPA) axis suppression 1
For trunk and extremities, apply low to medium potency topical corticosteroids once to twice daily for 1-2 weeks depending on response 1
For face, neck, and skin folds, never use ultra-high-potency corticosteroids in these areas due to high risk of skin atrophy 1

Apply emollients liberally and frequently to restore skin barrier function throughout the treatment course 1
Use oral antihistamines as adjunctive therapy for pruritus control, particularly helpful at bedtime to reduce nocturnal scratching 1
Implement allergen avoidance as the cornerstone of management once the causative agent is identified through patch testing 2

Perform patch testing in children with persistent eczematous eruptions, particularly those with hand and eyelid eczema, as allergic contact dermatitis in children is increasing 3, 4
Common pediatric allergens include nickel, topical antibiotics, preservative chemicals, fragrances, and rubber accelerators 3, 4

Do not use oral corticosteroids routinely in pediatric plant contact dermatitis or mild-to-moderate contact dermatitis 1
Avoid topical antibiotics routinely, as they increase resistance and sensitization risk 1, 5
Do not use barrier creams as primary protection, as they confer a false sense of security and are of questionable value in protecting against irritants 6

For severe cases resistant to topical therapy, consider wet-wrap therapy with topical corticosteroids for 3-7 days (possibly extending to 14 days in severe cases) 5
For facial and intertriginous areas, topical calcineurin inhibitors (tacrolimus 0.03% ointment or pimecrolimus 1% cream) are preferred in children aged 2 years and above to avoid skin atrophy 5

Overlooking allergen identification can lead to poor long-term prognosis with only 25% complete healing in occupational cases 2, 6